tirzepatide and svt (ZEPBOUND) Approved for Chronic Weight Management in Adults with Obesity ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Learn more about Tirzepatide_Industry News_Senova

Patients with hypertension should receive appropriate first-line antihypertensive therapy according to NICE hypertension guidelines (NG136), which recommend ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, or thiazide-like diuretics as initial treatment depending on age, ethnicity, and comorbidities

"A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies"

If headaches persist beyond this window, a provider review of dose, hydration protocol, and potential contributors is warranted

Semaglutide and Cardiovascular Outcomes [PMID: 38381682] Laboratory literature summary: Semaglutide and Cardiovascular Outcomes